All Updates

All Updates

icon
Filter
Product updates
Partnerships
Insilico Medicine delivers second preclinical candidate compound to Fosun Pharma
AI Drug Discovery
Jul 5, 2024
This week:
Partnerships
MGI Tech and Predica Diagnostics collaborate to develop Predica's targeted RNA sequencing tests
Precision Medicine
Jul 11, 2024
Partnerships
Renalytix partners with Steno Diabetes Center to advance precision medicine solutions for diabetes and chronic kidney disease
Precision Medicine
Jul 11, 2024
Partnerships
Myriad Genetics and Personalis cross-license patents for tumor-informed cancer treatment tests
Precision Medicine
Jul 11, 2024
Funding
Element Biosciences raises USD 277 million in Series D funding to commercialize AVITI DNA sequencer and support AVITI24 launch
Precision Medicine
Jul 11, 2024
Funding
Jacobi Robotics raises USD 5 million in seed funding to expand capacity
Smart Factory
Jul 11, 2024
M&A
Formlabs acquires Micronics for undisclosed sum to develop next-generation SLS printers
Additive Manufacturing
Jul 11, 2024
Partnerships
Anthropic partners with Amazon Bedrock to fine-tune Claude 3 Haiku model
Foundation Models
Jul 11, 2024
Funding
Lemon.markets raises EUR 12 million in funding to support growth
FinTech Infrastructure
Jul 11, 2024
M&A
Kipu Quantum acquires PlanQK platform to enhance accessibility to quantum computing solutions
Quantum Computing
Jul 11, 2024
Partnerships
Quantinuum and STFC Hartree Centre partner to enhance quantum computing accessibility in UK
Quantum Computing
Jul 11, 2024
AI Drug Discovery

AI Drug Discovery

Jul 5, 2024

Insilico Medicine delivers second preclinical candidate compound to Fosun Pharma

Product updates
Partnerships

  • AI-powered drug developer Insilico Medicine has completed the second preclinical candidate compound (PCC) in collaboration with Fosun Pharma. This compound is potentially a new therapeutic for treating solid tumors using a synthetic lethal strategy. The companies expect to submit the candidate for pre-IND application by Q4 2024.

  • The compound targets DNA damage repair mechanisms, a significant aspect of tumor therapy. The process leveraged Insilico’s PandaOmics, an AI target identification engine, and Life Star 1, an AI-operated lab. Chemistry42, another AI tool, created compounds expressly for the target. The compound is claimed to have shown promising results in preclinical studies, with anti-tumor efficacy and impressive ADMET properties. Fosun Pharma plans to take on the compound for further research and development after Insilico advances it to the IND-enabling stage.

  • Analyst QuickTake : The partnership between Insilico Medicine and Fosun Pharma was established in January 2022 . It was aimed to develop multiple drug targets, including Insilico’s Glutaminyl-peptide cyclotransferase-like (QPCTL) program, and to develop Fosun’s internal drug development programs using Insilico's PandaOmics and Chemistry42 platforms.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.